Down-regulation and Clinical Implication of Galectin-9 Levels in Patients with Acute Coronary Syndrome and Chronic Kidney Disease

Abstract

In various autoimmune diseases, Galecin-9 (Gal-9) has been shown to regulate the T-cell balance by decreasing Th1 and Th17, while increasing the number of regulatory T cells (Tregs). However, the role of Gal-9 in the patients with acute coronary syndrome (ACS) and chronic kidney disease (CKD) remains unclear. This study aims to measure the Gal-9 levels in serum and peripheral blood mononuclear cells (PBMCs) in patients with ACS plus CKD and examine their clinical implication. The serum levels of Gal-9 were determined by enzyme-linked immunosorbent assay (ELISA), the expression levels of Gal-9, Tim-3, and Foxp3 mRNA in PBMCs were detected by real-time reverse transcription-polymerase chain reaction (RT-PCR), and the expression of Gal-9 on the surface of PBMCs and in PBMCs was analyzed by flow cytometry. Furthermore, the correlation of serum Gal-9 levels with anthropometric and biochemical variables in patients with ACS plus CKD was analyzed. The lowest levels of Gal-9 in serum and PBMCs were found in the only ACS group, followed by the ACS+CKD group, and the normal coronary artery (NCA) group, respectively. Serum Gal-9 levels were increased along with the progression of glomerular filtration rate (GFR) categories of G1 to G4. Additionally, serum Gal-9 levels were negatively correlated with high-sensitivity C-reactive protein (hs-CRP), estimated GFR (eGFR), and lipoprotein(a), but positively with creatinine, age, osmotic pressure, and blood urea nitrogen (BUN). Notably, serum Gal-9 was independently associated with hs-CRP, osmotic pressure, and lipoprotein(a). Furthermore, serum Gal-9 levels were elevated in patients with type 2 diabetes (T2DM) and impaired glucose tolerance (IGT) in ACS group. It was suggested that the levels of Gal-9 in serum and PBMCs were decreased in patients with simple ACS and those with ACS plus CKD, and hs-CRP, eGFR, osmotic pressure and T2DM may have an influence on serum Gal-9 levels.

Keywords

Galectin-9 / inflammation / acute coronary syndrome / chronic kidney disease

References

[1] LibbyP. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol, 2012, 32(9): 2045-2051

[2] HanssonGK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med, 2005, 352: 1685-1695

[3] HanssonGK. Innate and Adaptive Immunity in the Pathogenesis of Atherosclerosis. Circ Res, 2002, 91(4): 281-291

[4] LauratE, PoirierB, TupinE, et al.. In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice. Circulation, 2001, 104: 197-202

[5] MetheH, BrunnerS, WiegandD, et al.. Enhanced T-helper-1 lymphocyte activation patterns in acute coronary syndromes. J Am Coll Cardiol, 2005, 45(12): 1939-1945

[6] ChengX, LiaoYH, GeH, et al.. TH1/TH2 functional imbalance after acute myocardial infarction: coronary arterial inflammation or myocardial inflammation. J Clin Immunol, 2005, 25(3): 246-253

[7] ChengX, YuX, DingYJ, et al.. The Th17/Treg imbalance in patients with acute coronary syndrome. Clin Immunol, 2008, 127(1): 89-97

[8] KishoreU, EggletonP, ReidKB, et al.. Modular organization of carbohydrate recognition domains in animal lectins. Matrix Biology, 1997, 15: 583-592

[9] ZhuC, AndersonAC, SchubartA, et al.. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol, 2005, 6(12): 1245-1252

[10] KashioY, NakamuraK, AbedinMJ, et al.. Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway. J Immunol, 2003, 170(7): 3631-3636

[11] WangF, XuJ, LiaoY, et al.. Tim-3 ligand galectin-9 reduces IL-17 level and accelerates Klebsiella pneumoniae infection. Cell Immunol, 2011, 269(1): 22-28

[12] OomizuS, ArikawaT, NikiT, et al.. Galectin-9 suppresses Th17 cell development in an IL-2-dependent but Tim-3-independent manner. Clin Immunol, 2012, 143(1): 51-58

[13] BiS, EarlLA, JacobsL, et al.. Structural features of galectin-9 and galectin-1 that determine distinct T cell death pathways. J Biol Chem, 2008, 283(18): 12 248-12 258

[14] WangF, WanL, ZhangC, et al.. Tim-3-Galectin-9 pathway involves the suppression induced by CD4+CD25+ regulatory T cells. Immunobiology, 2009, 214(5): 342-349

[15] SekiM, OomizuS, SakataKM, et al.. Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. Clin Immunol, 2008, 127(1): 78-88

[16] ChouFC, ShiehSJ, SytwuHK. Attenuation of Th1 response through galectin-9 and T-cell Ig mucin 3 interaction inhibits autoimmune diabetes in NOD mice. Eur J Immunol, 2009, 39(9): 2403-2411

[17] KanzakiM, WadaJ, SugiyamaK, et al.. Galectin-9 and T cell immunoglobulin mucin-3 pathway is a therapeutic target for type 1 diabetes. Endocrinology, 2012, 153(2): 612-620

[18] LeitnerJ, RiegerA, PicklWF, et al.. TIM-3 does not act as a receptor for galectin-9. PLoS Pathog, 2013, 9(3): e1003253

[19] VaitaitisGM, WagnerDHJr.. Galectin-9 controls CD40 signaling through a Tim-3 independent mechanism and redirects the cytokine profile of pathogenic T cells in autoimmunity. PLoS One, 2012, 7(6): e38708

[20] SuEW, BiS, KaneLP. Galectin-9 regulates T helper cell function independently of Tim-3. Glycobiology, 2011, 21(10): 1258-1265

[21] FoksAC, RanIA, WassermanL, et al.. T-cell immunoglobulin and mucin domain 3 acts as a negative regulator of atherosclerosis. Arterioscler Thromb Vasc Biol, 2013, 33(11): 2558-2565

[22] KuroseY, WadaJ, KanzakiM, et al.. Serum galectin-9 levels are elevated in the patients with type 2 diabetes and chronic kidney disease. BMC Nephrology, 2013, 14: 23

[23] ZhuR, LiuC, TangH, et al.. Serum Galectin-9 Levels Are Associated with Coronary Artery Disease in Chinese Individuals. Mediators Inflamm, 2015, 2015: 457167

[24] LeveyAS, de JongPE, CoreshJ, et al.. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int, 2011, 80(1): 17-28

[25] MatsuoS, ImaiE, HorioM, et al.. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis, 2009, 53(6): 982-992

[26] GotsmanI, GrabieN, GuptaR, et al.. Impaired regulatory T-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule. Circulation, 2006, 114(19): 2047-2055

[27] MorA, PlanerD, LuboshitsG, et al.. Role of naturally occurring CD4+ CD25+ regulatory T cells in experimental atherosclerosis. Arterioscler Thromb Vasc Biol, 2007, 27(4): 893-900

[28] XieJJ, WangJ, TangTT, et al.. The Th17/Treg functional imbalance during atherogenesis in ApoE(-/-) mice. Cytokine, 2010, 49(2): 185-193

[29] KoguchiK, AndersonDE, YangL, et al.. Dysregulated T cell expression of TIM3 in multiple sclerosis. J Exp Med, 2006, 203(6): 1413-1418

[30] ChabotSKY, SekiM, ShiratoY, et al.. Regulation of galectin-9 expression and release in Jurkat T cell line cells. Glycobiology, 2002, 12: 111-118

[31] DelacourD, KochA, JacobR. The role of galectins in protein trafficking. Traffic, 2009, 10(10): 1405-1413

[32] ChiricoWJ. C Protein release through nonlethal oncotic pores as an alternative nonclassical secretory pathway. BMC Cell Biol, 2011, 12: 46

[33] CorsonMA. Emerging inflammatory markers for assessing coronary heart disease risk. Current Cardiology Reports, 2009, 11: 452-459

[34] WeberC, NoelsH. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med, 2011, 17(11): 1410-1422

[35] ChengXW, KikuchiR, IshiiH, et al.. Circulating cathepsin K as a potential novel biomarker of coronary artery disease. Atherosclerosis, 2013, 228(1): 211-216

[36] DrakopoulouM, ToutouzasK, StefanadiE, et al.. Association of inflammatory markers with angiographic severity and extent of coronary artery disease. Atherosclerosis, 2009, 206(2): 335-339

[37] Noren HootenN, EjioguN, ZondermanAB, et al.. Association of oxidative DNA damage and C-reactive protein in women at risk for cardiovascular disease. Arterioscler Thromb Vasc Biol, 2012, 32(11): 2776-2784

[38] Arroyo-EspligueroR, AvanzasP, Cosin-SalesJ, et al.. C-reactive protein elevation and disease activity in patients with coronary artery disease. Eur Heart J, 2004, 25(5): 401-408